Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495858 | 1.00 | BACE1 (0.35) | BACE1TGM2CYP26A1CYP26B1NR1H3 | |
| SCHEMBL4495046 | 0.95 | BACE1 (0.35) | BACE1TGM2CYP26A1CYP26B1CSF1R | |
| SCHEMBL4495040 | 0.95 | BACE1 (0.35) | BACE1TGM2CYP26A1CYP26B1CSF1R | |
| SCHEMBL223984 | 0.92 | BACE1 (0.35) | BACE1TGM2CSF1RHDAC1NR1H4 | |
| SCHEMBL223985 | 0.92 | BACE1 (0.35) | BACE1TGM2CSF1RHDAC1NR1H4 | |
| SCHEMBL4502082 | 0.92 | BACE1 (0.33) | BACE1TGM2PDGFRBMEN1KMT2A | |
| SCHEMBL4502077 | 0.92 | BACE1 (0.33) | BACE1TGM2PDGFRBMEN1KMT2A | |
| SCHEMBL4492148 | 0.91 | KDM4E (0.34) | CYP26A1CYP26B1CSF1RHDAC1NR1H4 | |
| SCHEMBL4492150 | 0.91 | KDM4E (0.34) | CYP26A1CYP26B1CSF1RHDAC1NR1H4 | |
| SCHEMBL4488158 | 0.90 | BACE1 (0.36) | BACE1TGM2CYP26A1CYP26B1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | BACE1 1615/4885TGM2 4379/4885CYP26A1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.